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Abstract
Background: Activation of the complement system plays an important role in the regulation of immune and
inflammatory reactions, and contributes to inflammatory responses triggered by envenomation provoked by
Bothrops snakes. The present study aimed to assess whether Bothrops jararacussu and Bothrops pirajai crude venoms
and their isolated toxins, namely serine protease (BjussuSP-I) and L-amino acid oxidase (BpirLAAO-I), modulate
human complement system pathways.
Methods: Lyophilized venom and toxin samples solubilized in phosphate buffered saline were diluted in
appropriate buffers to evaluate their hemolytic activity on the alternative and classical pathways of the complement
system. Venom- and toxin-treated normal human serum was added to the erythrocyte suspension, and the kinetic
of hemolysis was measured spectrophotometrically at 700 nm. The kinetic 96-well microassay format was used for
this purpose. We determined the t½ values (time required to lyse 50 % of target erythrocytes), which were
employed to calculate the percentage of inhibition of the hemolytic activity promoted by each sample
concentration. To confirm complement system activation, complement-dependent human neutrophil migration
was examined using the Boyden chamber model.
Results: At the highest concentration tested (120 μg/mL), B. jararacussu and B. pirajai crude venoms inhibited the
hemolytic activity of the classical pathway (65.3 % and 72.4 %, respectively) more strongly than they suppressed the
hemolytic activity of the alternative pathway (14.2 and 13.6 %, respectively). BjussuSP-I (20 μg/mL) did not affect the
hemolytic activity of the classical pathway, but slightly decreased the hemolytic activity of the alternative pathway
(13.4 %). BpirLAAO-I (50 μg/mL) inhibited 24.3 and 12.4 % of the hemolytic activity of the classical and alternative
pathways, respectively. Normal human serum treated with B. jararacussu and B. pirajai crude venoms induced
human neutrophil migration at a level similar to that induced by zymosan-activated normal human serum.
Conclusion: Together, the results of the kinetics of hemolysis and the neutrophil chemotaxis assay suggest that
pre-activation of the complement system by B. jararacussu and B. pirajai crude venoms consumes complement
components and generates the chemotactic factors C3a and C5a. The kinetic microassay described herein is useful
to assess the effect of venoms and toxins on the hemolytic activity of the complement system.
Keywords: Bothrops jararacussu, Bothrops pirajai, Chemotaxis, Complement system, Kinetic microassay, L-amino acid
oxidase, Serine protease, Snake venom
* Correspondence: lupcrott@usp.br
Departamento de Análises Clínicas, Toxicológicas e Bromatológicas,
Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São
Paulo (USP), Avenida do Café, s/n, Ribeirão Preto, SPCEP 14040–903, Brasil
© 2015 Ayres et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ayres et al. Journal of Venomous Animals and Toxins
including Tropical Diseases  (2015) 21:29 
DOI 10.1186/s40409-015-0026-7
Background
Snakes of the genus Bothrops account for the majority of
snakebites in Latin America [1]. Several signs and symp-
toms follow Bothrops envenomation, which are associ-
ated with both local effects – such as myonecrosis,
hemorrhage, edema and dermonecrosis – and systemic
disorders – characterized by coagulopathy, hemorrhage,
hypertension, cardiovascular shock and acute renal fail-
ure [2].
Bothrops snake venoms trigger a typical local inflamma-
tory response that involves edema and the subsequent
mobilization of leukocytes. However, it is still not clear
how Bothrops snake venoms elicit leukocyte recruitment,
which is essential to restore tissue homeostasis and repair
the injured sites. Studies on B. asper venom suggest that
the activation of the complement system (CS) is one of
the mechanisms underlying this event [3].
Bothrops venoms are a complex mixture of compo-
nents including phospholipases A2, metalloproteases,
serine proteases (SPs) and L-amino acid oxidases
(LAAOs) that exert different pharmacological and bio-
chemical activities [4–6]. There are evidences that the
inflammatory response elicited by Bothrops toxins is
mainly mediated by phospholipases A2 and metallopro-
teases [4, 7]. However, the possible participation of snake
venom SPs and LAAOs in the course of the inflamma-
tory response, including activation of the CS, should not
be discarded [5].
Human CS is composed of about 35 to 40 proteins
and glycoproteins present in blood plasma or on cell
surfaces [8]. The CS performs important biological func-
tions in the maintenance and regulation of immune and
inflammatory reactions. Its proteins interact with each
other in a highly regulated manner to promote inflam-
mation and destroy invading microorganisms and for-
eign cells. As the CS has the potential to damage host
tissues, regulatory proteins tightly control the activation
and activity of this system [9].
The complement system can be activated via three dis-
tinct pathways – classical (CS-CP), alternative (CS-AP)
or lectin (CS-LP) – depending on the stimulus type. The
CS-CP is activated when C1, the first component of the
CS cascade, binds to an antibody molecule complexed
with an antigen. The CS-AP is activated by spontaneous
hydrolysis of the C3 component and subsequent depos-
ition of C3 fragments on activating surfaces [10]. The
CS-LP, more recently discovered, is activated through
recognition of carbohydrates on the surface of microor-
ganisms by mannose binding lectins [11]. The CS activa-
tion entails sequential proteolytic reactions, a process
called CS cascade, which generates products with a var-
iety of biological activities such as anaphylaxis, chemo-
taxis, opsonization, solubilization of immune complexes,
and modulation of the immune response [12].
Although the effect of snake venoms on the CS activity
has already been reported, much remains to be investi-
gated, in particular with regard to the action of SPs and
LAAOs [13–15]. Snake venom SPs act mainly on compo-
nents of the coagulation cascade, which in turn leads to a
hemostatic imbalance [16, 17]. Flavoxobin, a SP from Tri-
meresurus flavoviridis snake venom, specifically cleaves
the human complement protein C3, thus acting as a C3
convertase enzyme [18]. The biological effects of snake
venom LAAOs usually proceed through induction of
apoptosis, cytotoxicity, and inhibition or induction of both
platelet aggregation and microbicidal activity [19–23].
To date, there are no reports on the action of the
L-amino acid oxidase isolated from B. pirajai venom
(BpirLAAO-I) on the complement system. In order to
broaden the existing knowledge on the biological prop-
erties of Bothrops snake venom, the present study aims
to assess whether B. jararacussu (Bjussu) crude venom
and its serine protease (BjussuSP-I), as well as B. pirajai
(Bpir) crude venom and its LAAO (BpirLAAO-I), modu-
late the human CS pathways.
Methods
Snake venoms and toxins
The lyophilized Bpir and Bjussu crude venoms were ac-
quired from the snake house of Bioagents Bioactive Pro-
teins Ltd. (Batatais, SP, Brazil). BpirLAAO-I was purified
by the three-step chromatographic process reported by
Izidoro et al. [24], which employed Sephadex G-75,
Benzamidine-Sephadex, and Phenyl-Sepharose as sta-
tionary phases. The purity of the final preparation was
higher than 95 %. The BpirLAAO-I enzymatic activity
was determined before performing the experiments.
BjussuSP-I was isolated by a three-step chromatographic
process that used Sephacryl S-200, Benzamidine Sephar-
ose, and C2/C18 as stationary phases, as described by
Menaldo et al. [17].
Animals
Two adult female New Zealand white rabbits, weighing
approximately 3.3 kg, and two adult sheep were obtained
from the Central Animal Facility of the University of São
Paulo, campus of Ribeirão Preto (USP-RP). The rabbits
were kept in the vivarium at the School of Pharmaceut-
ical Sciences of Ribeirão Preto (FCFRP/USP).
Blood was collected from the rabbit’s central ear artery
or the sheep’s jugular vein into an equal volume of
modified Alsever’s solution as anticoagulant, and further
employed to assay the hemolytic activity of the CS.
Normal human serum (NHS)
Ten milliliter of blood from healthy volunteers of both
genders, aged from 20 to 50 years, were collected in the ab-
sence of anticoagulants to obtain normal human serum
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(NHS). The sera were separated by centrifugation at 500 × g
for ten minutes at 4 °C, pooled, aliquoted into polyethylene
tubes, and frozen at −80 °C. NHS pool was employed to
evaluate the immunomodulatory activity of Bjussu and Bpir
crude venoms and their isolated toxins on the CS activity
and the CS-dependent neutrophil chemotaxis.
Human CS modulation by venoms and toxins
Preparation of sheep erythrocytes to assay the CS-CP/LP
activity
Sheep erythrocyte suspension was prepared as previously
described [17]. Briefly, the anticoagulated sheep blood
was diluted in triethanolamine (TEA) buffer containing
Ca2+ and Mg2+ (TEA-Ca2+-Mg2+ buffer) and centri-
fuged. After discarding the plasma and buffy coat, the
erythrocytes were washed and suspended to a concentra-
tion of approximately 5 % (1.2 × 109 cells/mL). This sus-
pension was mixed with an appropriate dilution of
hemolysin and incubated for 15 min, at 4 °C. Final ab-
sorbance of the suspension was adjusted to an optical
density ranging from 0.7 to 0.8 at 700 nm (SpectraMax®
Plus spectrophotometer, Molecular Devices, USA).
Preparation of rabbit erythrocytes to assay the
CS-AP activity
Rabbit erythrocyte suspension was prepared as described
[17]. Briefly, the anticoagulated rabbit blood was filtered,
diluted in an equal volume of a Ca2+ and Mg2+-chelating
solution composed of TEA and EDTA (ethylenediamine
tetraacetic acid), and incubated for 15 min, at 37 °C.
After washing three times with TEA-Mg2+ buffer, the
erythrocytes were suspended in modified Alsever’s solu-
tion supplemented with 0.05 % sodium azide, in a vol-
ume equal to twice the original blood volume. Finally,
the erythrocyte suspension was divided into aliquots and
stored at 4 °C.
Prior to use in the hemolytic assay, the erythrocytes were
washed three times with TEA-EGTA-Mg2+ buffer [EGTA:
ethylene glycol-bis (2-aminoethylether)-N,N,N',N'-tetraacetic
acid], and suspended in this buffer. Final absorbance of the
suspension was adjusted to an optical density ranging from
0.7 to 0.8 by spectrophotometric reading at 700 nm.
Measurement of the hemolytic activity of the CS using the
kinetic method
The residual hemolytic activity of the CS in NHS treated
with either crude venoms or isolated toxins was assessed
through the kinetic 96-well microassay, as previously de-
scribed [17]. Bjussu and Bpir crude venoms (3.1-120 μg/
mL), and the toxins BjussuSP-I (0.6-20 μg/mL) and
BpirLAAO-I (1.6-50 μg/mL) were diluted in appropriate
buffers – TEA-Ca2+-Mg2+ buffer to assay the CS-CP/LP
activity or TEA-EGTA-Mg2+ buffer to assay the CS-AP
activity – to the concentrations indicated in parentheses.
These samples were incubated with NHS in 96-well mi-
croplates for one hour, at 37 °C, in a final volume of
200 μL. Aliquots of sensitized sheep erythrocytes (CS-
CP/LP) or rabbit erythrocytes (CS-AP) were added to
the wells and the kinetics of hemolysis was followed by
uninterrupted recording of absorbance at 700 nm for
15 min (SpectraMax Plus Microplate Reader, Molecular
Devices, USA).
The time-course curve of hemolysis was used to deter-
mine the time required to lyse 50 % of the erythrocytes
(t½), which corresponds to the time required for the ab-
sorbance to decline to half of its initial value. The t½ value
is directly proportional to the percentage of suppression
of the hemolytic activity of the CS, which was calculated
for each sample concentration, as follows [17, 25]:
Hemolysis inhibitionð%Þ ¼ 100 t
1




These percentages of inhibition values were fitted to a
linear regression curve to determine the IC50 value,
which is the venom or toxin concentration that inhibits
50 % of hemolysis. To obtain accurate IC50 values, at
least one of the values of percentage of inhibition must
be greater than 50 %.
Assay of CS-dependent neutrophil chemotaxis
Serum treatment
Aliquots of NHS were treated with zymosan or venom as
previously described [26]. The amount of crude venom
used in the chemotaxis assay was calculated based on the
amount of venom that best inhibited the hemolytic activ-
ity of CS-CP/LP, 120 μg/mL, which corresponds to 3.3 μg
of venom for each 1 μL of NHS. Briefly, Bjussu and Bpir
crude venoms (400 μg) diluted in TEA-Ca2+-Mg2+ buffer
(final volume of 100 μL) were incubated for 40 min, at
37 °C, with 120 μL of: NHS, heat-inactivated NHS (56 °C,
30 min), or TEA-Ca2+-Mg2+ buffer. Zymosan-activated
NHS and NHS incubated with TEA-Ca2+-Mg2+ buffer
were used as positive and negative controls, respectively.
To inactivate residual complement, the supernatants were
collected and heated to 56 °C for 30 min. Finally, the su-
pernatants were diluted 1:5 in Hanks buffered saline solu-
tion (HBSS) to be used in the chemotaxis assay.
Human neutrophils isolation
Human neutrophils were isolated from peripheral blood
of healthy volunteers using the Ficoll-Hypaque discon-
tinuous density gradient method. Histopaque-1077 was
layered over Histopaque-1119, and the blood samples
were processed according to the manufacturer's instruc-
tions (Sigma Diagnostics, Inc., USA). After washing the
cell pellets with HBSS, the concentration of the neutro-
phil suspension was adjusted to 2 × 106 cells/mL.
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Chemotaxis assay
The neutrophil chemotaxis assay was performed using a
modified Boyden chamber, as previously described [27].
Briefly, the lower chamber was filled with 200 μL of
treated NHS and covered with a filter (diameter: 13 mm,
pore size: 3 μm, SSWPO1300, Millipore Corp., USA). The
upper compartment was filled with 300 μL of neutrophil
suspension. After 30 min of incubation at 37 °C in hu-
midified air, the filters were removed, fixed in 2-propanol,
stained with Harris hematoxylin, dehydrated in 2-
propanol, cleared with xylene, and mounted with Entellan®
mounting media (Merck, Germany). The neutrophil mi-
gration was determined by the leading front technique,
which measures the greatest distance in micrometers
crossed by three cells per field with a 100× magnification
[28]. At least ten fields per filter were examined.
Ethics committee approval
The Research Ethics Committee of FCFRP/USP ap-
proved the experimental procedures involving human
cells and sera, which were registered under CEP/FCFRP
n. 125/2008. The Ethics Committee on Laboratory Ani-
mal Care and Use at USP-RP approved the animal hous-
ing and handling procedures, as well as the experimental
protocols involving animal cells, which were registered
under CEUA n. 08.1.362.53.0/2008.
Statistical analyses
Experimental data were analyzed by One-way ANOVA
followed by the Bonferroni's post-hoc test, with the aid of
the GraphPad Prism Software (version 5.0, GraphPad Soft-
ware, USA). Values of p < 0.05 were considered significant.
Results
Modulation of the hemolytic activity of the CS
To assess whether Bjussu and Bpir crude venoms and the
isolated toxins BjussuSP-I and BpirLAAO-I modulate the
hemolytic activity of the CS, we measured the residual
hemolytic activity of CS in sera treated with these sam-
ples, using the kinetic microassay. To conduct separate
analysis of the sample effects on CS-CP/LP and CS-AP,
we employed sheep erythrocytes suspended in TEA-
Ca2+-Mg2+ buffer and rabbit erythrocytes suspended in
TEA-EGTA-Mg2+ buffer, respectively. The obtained re-
sults are reported below, where the increase in t½ values
means suppression of the hemolytic activity of CS.
Bjussu and Bpir crude venoms selectively suppress the
hemolytic activity of the CS
Bjussu and Bpir crude venoms augmented the time re-
quired to lyse 50 % of erythrocytes (t½) values (i.e. di-
minished the hemolytic activity) for both CS pathways
studied, in a concentration-dependent manner. Such
increase was statistically significant at concentrations
higher than 50 μg/mL and 12.5 μg/mL for the CS-CP/
LP and the CS-AP, respectively (Fig. 1a-d). Bjussu and
Bpir crude venoms similarly inhibited the hemolytic ac-
tivity of the CS-CP/LP, yielding mean IC50 values of
91.2 μg/mL and 86.9 μg/mL, respectively (Fig. 1e-f ).
It was not possible to determine the IC50 values for
the CS-AP because the highest Bjussu and Bpir crude
venom concentration tested (120 μg/mL) suppressed less
than 50 % of the hemolytic activity: 14.2 and 13.6 %, re-
spectively. At this concentration, Bjussu and Bpir crude
venom reduced the hemolytic activity of the CS-CP/LP
by 65.3 and 72.4 %, respectively. Therefore, Bjussu and
Bpir crude venoms inhibited the hemolytic activity of
the CS-CP/LP more effectively than they inhibited the
hemolytic activity of the CS-AP.
The isolated toxins BjussuSP-I and BpirLAAO-I inhibit the
hemolytic activity of the CS
In the range of concentrations tested (0.6-20 μg/mL),
BjussuSP-I did not significantly alter the t½ values for
the CS-CP/LP (Fig. 2a). On the other hand, this toxin
significantly augmented the t½ values for the CS-AP at
2.5, 10, and 20 μg/mL (Fig. 2c). BpirLAAO-I significantly
increased the t½ values for the CS-CP/LP at all concentra-
tions tested (Fig. 2b), and the t½ values for the CS-AP at the
concentrations of 3.1, 12.5, 25, and 50 μg/mL (Fig. 2d).
Although BjussuSP-I and BpirLAAO-I exerted
concentration-dependent effects, it was not possible to
determine their IC50 values. At the highest concentration
tested, BjussuSP-I inhibited the hemolytic activity of the
CS-AP by 13.4 %, while BpirLAAO-I suppressed the
hemolytic activity of CS-CP/LP and CS-AP by 24.3 and
12.4 %, respectively. Therefore, compared with the crude
venoms, the isolated toxins weakly inhibit the hemolytic
activity of both pathways of the CS.
Bjussu and Bpir crude venom-treated sera induce
neutrophil chemotaxis
Bjussu and Bpir crude venom, the samples that most
strongly inhibited the hemolytic activity of CS, were
assessed for their ability to modulate the human neu-
trophil chemotaxis. The venoms alone, i.e. incubated
with the CS-CP buffer in the absence of NHS, did not
elicit neutrophil migration. The mean distances of mi-
gration induced by NHS alone (negative control) were
23.7 μm and 23.5 μm (Fig. 3a and b, respectively).
The Bjussu and Bpir crude venom-treated NHS and
zymosan-treated NHS equally induced neutrophil mi-
gration (Fig. 3). The mean distances of migration in-
duced by Bjussu and Bpir crude venom-treated NHS
were 49.7 μm and 48.1 μm, respectively, and 53.5 μm
(Fig. 3a) and 50.4 μm (Fig. 3b) for zymosan-treated
NHS. Heat-inactivated NHS treated with Bjussu and
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Bpir crude venoms slightly stimulated neutrophil mi-
gration (28.0 μm and 26.7 μm, respectively). Thus,
pre-treatment of NHS with Bjussu and Bpir crude
venoms generate chemotactic factors.
Discussion
Snake venoms consist of complex mixtures of proteins
that affect different systems in the human organism, in-
cluding the CS [1, 14, 15, 29]. Venoms of snakes belonging
to the Crotalidae and Viperidae families contain a variety
of proteins that modulate the CS activity [30]. These mol-
ecules may directly cleave CS proteins such as C2, C3, and
C4 and stabilize the C3-convertase of the CS-AP, which
in turn amplifies the activation cascade [13, 31, 32].
Consequently, the production of the anaphylatoxins
C3a and C5a and other fragments of the CS activation,
such as C3b and C4b, is increased [13, 31, 32]. Venoms
of snakes from the Elapidae family also contain mole-
cules capable of activating the CS. These venoms re-
duce the hemolytic activity of the CS and convert C3
into products whose electrophoretic mobilities are dis-
tinct from those of the native C3 molecule in human
serum [33].
In this study, treatment of NHS with Bjussu and Bpir
crude venoms markedly reduced the hemolytic activity
of the CS-CP/LP, which indicates that these venoms are
potential modulators of this CS pathway. These find-
ings are consistent with another study showing that the
Fig. 1 Effect of Bjussu and Bpir crude venom on the hemolytic activity of the complement system. This figure depicts the concentration-dependent
inhibitory effect of (a, c, and e) Bjussu and (b, d, and f) Bpir crude venoms on the hemolytic activity of the (a, b, e, and f) classical and (c and d) alternative
pathways of the complement system. Panels a to d: Control represents normal human serum incubated with buffer alone. Data are expressed as the
mean ± standard deviation of the t½ values obtained for each venom concentration, based on three (CS-CP/LP) or two (CS-AP) independent experiments
assayed in triplicate. *p< 0.05, **p< 0.001, or ***p< 0.0001 vs. control. Panels e and f: Linear regression graph, where the X-values represent the amount of
(e) Bjussu and (f) Bpir crude venom (in μg/mL) and the Y-values represent the mean percentages of hemolytic activity inhibition. The IC50 values were
calculated from three independent experiments. Bjussu: Bothrops jararacussu; Bpir: Bothrops pirajai; t½: time required to lyse 50 % of erythrocytes
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hemolytic activity of serum samples incubated for one
hour at 37 °C with B. atrox venom fractions was re-
duced by more than 85 % [34]. In contrast, Bjussu and
Bpir crude venoms only weakly inhibited the hemolytic
activity of the CS-AP.
Regarding the isolated toxin BpirLAAO-I, this is the
first study to demonstrate its negative modulatory effect
on the hemolytic activity of the CS-CP/LP and CS-AP.
This toxin increased the t½ values for both CS pathways
at almost all the concentrations tested. On the other hand,
Fig. 3 Chemotactic response of neutrophils to serum treated with (a) Bjussu and (b) Bpir crude venom. Normal human serum (NHS) was treated
with crude venom, zymosan (positive control), or TEA-Ca2+-Mg2+ buffer (negative control). Crude venoms were also incubated with TEA-Ca2+-Mg2+buf-
fer alone or heat-inactivated NHS. Data are expressed as the mean ± standard deviation of three independent experiments assayed in
duplicate. *p < 0.05 or ***p < 0.0001 vs. negative control. Bjussu: Bothrops jararacussu; Bpir: Bothrops pirajai
Fig. 2 Effect of the toxins BjussuSP-I and BpirLAAO-I on the hemolytic activity of the complement system. This figure depicts the
concentration-dependent inhibitory effect of (a and c) BjussuSP-I and (b and d) BpirLAAO-I on the hemolytic activity of the (a and b)
classical and (c and d) alternative pathways of the complement system. Control represents normal human serum incubated with buffer
alone. Data are expressed as the mean ± standard deviation of the t½ values obtained for each toxin concentration, based on three (CS-
CP/LP) or two (CS-AP) independent experiments assayed in triplicate. *p < 0.05, **p < 0.001, or ***p < 0.0001 vs. control. BjussuSP-I: serine
protease isolated from Bothrops jararacussu crude venom; BpirLAAO-I: L-amino acid oxidase isolated from Bothrops pirajai crude venom; t½: time re-
quired to lyse 50 % of erythrocytes
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BjussuSP-I selectively inhibited the hemolytic activity of
the CS-AP, at least under the assessed conditions.
A recent study has demonstrated that two Bpir SPs,
named BpirSP41 and BpirSP27, similarly inhibit the
hemolytic activity of the CS-AP, but modulate the CS-CP/
LP at different levels: BpirSP41 suppress the hemolytic ac-
tivity of this CS pathway more strongly than BpirSP27
[17]. Flavoxobin, a SP isolated from Trimeresurus flavovir-
idissnake venom, activates the human CS-AP and leads
to the formation of membrane attack complex and to
the release of C3a and C5a. This SP was identified as a
heterologous C3 convertase that cleaves C3 directly and
selectively to form C3b and C3a [18].
The aforementioned results of the present study were
not able to elucidate whether the effects of Bjussu and
Bpir crude venoms and the isolated toxins BjussuSP-I
and BpirLAAO-I were due to: (i) a prior activation of
the CS during pre-incubation of the venom with NHS;
(ii) inactivation of CS components; (iii) interference in
the CS activation processes; and/or (iv) interaction with
CS regulators. Thus, other research strategies are re-
quired to unravel the mechanism of action of these
Bothrops venoms and toxins on the CS.
One strategy relies on the direct or indirect meas-
urement of possible fragments generated by the CS
activation. Induction of neutrophil chemotaxis by acti-
vated serum is an indirect method to assess the for-
mation of CS products C3a and C5a, which are potent
chemoattractants [35]. In this study, NHS treated with
Bjussu and Bpir crude venoms elicited neutrophil migra-
tion to levels similar to those elicited by zymosan-treated
NHS. Compared with the NHS alone, crude venoms alone
did not trigger neutrophil migration. These results led us
to conclude that crude venoms induced the cleavage of
C3 and C5 components of the CS in NHS, generating the
chemotactic fragments C3a and C5a. Previous studies
have reported that serum treated with B. asper and Tityus
serrulatus venoms were able to induce rat neutrophil mi-
gration. The authors have also proposed that the mechan-
ism of action of venoms involved the generation of CS
fragments with chemotactic activity [3, 25].
The production of the anaphylatoxins C3a and C5a
probably plays a role in in vivo inflammatory processes
that occur after Bothrops envenomation, such as edema,
coagulopathies, leukocyte mobilization, generation of re-
active oxygen species, and secretion of pro-inflammatory
cytokines like tumor necrosis factor alpha, interleukin-6,
and interleukin-1 [36].
Together, the results of the hemolytic activity of the
CS and the CS-dependent neutrophil chemotaxis dem-
onstrate that Bjussu and Bpir crude venoms activate
the CS. Our hypothesis is that the hemolytic activity
decrease is due to CS pre-activation during NHS incu-
bation with the venom. At that moment, components
of the CS are consumed – and thus generate CS frag-
ments, including anaphylatoxins C3a and C5a – which,
in turn, diminishes the amount of CS components
available to induce hemolysis. In summary, the CS pre-
activation by venom reduces the residual hemolytic ac-
tivity of NHS.
Furthermore, the kinetic microassay employed in this
study has proved to be useful for assessing the modula-
tory effect of snake venoms and toxins on the hemolytic
activity of different CS pathways. Compared with the
traditional hemolytic assay, the microassay requires
smaller volumes of reagents, and shorten the assay
length due to simultaneous analysis of many samples.
The results reported herein contribute to a better under-
standing of the mechanism of action of Bothrops venoms
and toxins.
Conclusion
Bjussu and Bpir crude venoms activate the CS-CP/LP
and generate the chemotactic factors C3a and C5a. As
the isolated toxins BjussuSP-I and BpirLAAO-I weakly
inhibited the human CS hemolytic activity, it is still ne-
cessary to perform further studies to isolate and identify
the Bjussu and Bpir venom components responsible for
the observed effects as well as to clarify the mechanisms
responsible for their biological effects.
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